Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.
Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Brian Yang
China FDA greenlights Lundbeck's Brintellix for severe depression, and more new drug approvals may be on the way. Physician education will be key for Brintellix, given relatively low number of psychiatrists in China.
The new month brings a flurry of personal moves in pharma’s corporate and regulatory landscape in Asia Pacific. AZ Japan has a new president, Takeda has a new GM for its incubator, and China's top health regulator appoints three high-level officials.
Sanofi has ventured deep into the digital health waters in China with an ambitious disease management plan covering 400 community clinics in 15 cities, in just a matter of months. To begin with, it is relying on partner Alibaba and its mobile health platform to progress plans.
After excluding China from its early development plans for domagrozumab, Pfizer’s rare disease R&D team is now gearing to commence a clinical study of the investigational compound on Duchenne muscular dystrophy patients soon.
Multinational drug makers continue shuffling their senior management in Asia as Gilead Sciences has a new president for Japan, and so does Bristol-Myers Squibb. WuXi NextCode hires a new chief digital officer.
AstraZeneca’s strong showing in China in the third quarter was driven by a combination of expanded coverage, investment in patient access efforts and an innovative commercial model. New introductions Tagrisso and Farxiga are also expected to add to the momentum.